Literature DB >> 35633443

Transcriptomic profiling of nonneoplastic cortical tissues reveals epileptogenic mechanisms in dysembryoplastic neuroepithelial tumors.

Krishan Kumar1, Aparna Banerjee Dixit1, Manjari Tripathi2, Vivek Dubey3, Fouzia Siraj4, Mehar Chand Sharma5, Sanjeev Lalwani6, P Sarat Chandra7, Jyotirmoy Banerjee8.   

Abstract

Low-grade dysembryoplastic neuroepithelial tumors (DNTs) are a frequent cause of drug-refractory epilepsy. Molecular mechanisms underlying seizure generation in these tumors are poorly understood. This study was conducted to identify altered genes in nonneoplastic epileptogenic cortical tissues (ECTs) resected from DNT patients during electrocorticography (ECoG)-guided surgery. RNA sequencing (RNAseq) was used to determine the differentially expressed genes (DEGs) in these high-spiking ECTs compared to non-epileptic controls. A total of 477 DEGs (180 upregulated; 297 downregulated) were observed in the ECTs compared to non-epileptic controls. Gene ontology analysis revealed enrichment of genes belonging to the following Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways: (i) glutamatergic synapse; (ii) nitrogen metabolism; (iii) transcriptional misregulation in cancer; and (iv) protein digestion and absorption. The glutamatergic synapse pathway was enriched by DEGs such as GRM4, SLC1A6, GRIN2C, GRM2, GRM5, GRIN3A, and GRIN2B. Enhanced glutamatergic activity was observed in the pyramidal neurons of ECTs, which could be attributed to altered synaptic transmission in these tissues compared to non-epileptic controls. Besides glutamatergic synapse, altered expression of other genes such as GABRB1 (synapse formation), SLIT2 (axonal growth), and PROKR2 (neuron migration) could be linked to epileptogenesis in ECTs. Also, upregulation of GABRA6 gene in ECTs could underlie benzodiazepine resistance in these patients. Neural cell-type-specific gene set enrichment analysis (GSEA) revealed transcriptome of ECTs to be predominantly contributed by microglia and neurons. This study provides first comprehensive gene expression profiling of nonneoplastic ECTs of DNT patients and identifies genes/pathways potentially linked to epileptogenesis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Dysembryoplastic neuroepithelial tumors; Patch clamp; RNA sequencing; Synaptic transmission; Transcriptomics

Mesh:

Substances:

Year:  2022        PMID: 35633443     DOI: 10.1007/s10142-022-00869-1

Source DB:  PubMed          Journal:  Funct Integr Genomics        ISSN: 1438-793X            Impact factor:   3.674


  57 in total

1.  Intrinsic epileptogenicity of gangliogliomas may be independent from co-occurring focal cortical dysplasia.

Authors:  Carmen Barba; Roland Coras; Flavio Giordano; Anna Maria Buccoliero; Lorenzo Genitori; Ingmar Blümcke; Renzo Guerrini
Journal:  Epilepsy Res       Date:  2011-08-09       Impact factor: 3.045

2.  An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors.

Authors:  V Bruno; G Battaglia; A Copani; V M Cespédes; M F Galindo; V Ceña; J Sánchez-Prieto; F Gasparini; R Kuhn; P J Flor; F Nicoletti
Journal:  Eur J Neurosci       Date:  2001-04       Impact factor: 3.386

3.  Altered expression of group I metabotropic glutamate receptors in the hippocampus of amygdala-kindled rats.

Authors:  M T Akbar; M Rattray; J F Powell; B S Meldrum
Journal:  Brain Res Mol Brain Res       Date:  1996-12-31

4.  Imaging blood-brain barrier dysfunction as a biomarker for epileptogenesis.

Authors:  Guy Bar-Klein; Svetlana Lublinsky; Lyn Kamintsky; Iris Noyman; Ronel Veksler; Hotjensa Dalipaj; Vladimir V Senatorov; Evyatar Swissa; Dror Rosenbach; Netta Elazary; Dan Z Milikovsky; Nadav Milk; Michael Kassirer; Yossi Rosman; Yonatan Serlin; Arik Eisenkraft; Yoash Chassidim; Yisrael Parmet; Daniela Kaufer; Alon Friedman
Journal:  Brain       Date:  2017-06-01       Impact factor: 13.501

Review 5.  Low-grade epilepsy-associated neuroepithelial tumours - the 2016 WHO classification.

Authors:  Ingmar Blümcke; Eleonora Aronica; Albert Becker; David Capper; Roland Coras; Mrinalini Honavar; Thomas S Jacques; Katja Kobow; Hajime Miyata; Angelika Mühlebner; José Pimentel; Figen Söylemezoğlu; Maria Thom
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

6.  Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy.

Authors:  E Aronica; B Yankaya; G H Jansen; S Leenstra; C W van Veelen; J A Gorter; D Troost
Journal:  Neuropathol Appl Neurobiol       Date:  2001-06       Impact factor: 8.090

7.  Local and remote epileptogenicity in focal cortical dysplasias and neurodevelopmental tumours.

Authors:  Sandrine Aubert; Fabrice Wendling; Jean Regis; Aileen McGonigal; Dominique Figarella-Branger; Jean-Claude Peragut; Nadine Girard; Patrick Chauvel; Fabrice Bartolomei
Journal:  Brain       Date:  2009-09-21       Impact factor: 13.501

8.  Enhanced endogenous activation of NMDA receptors in pyramidal neurons of hippocampal tissues from patients with mesial temporal lobe epilepsy: A mechanism of hyper excitation.

Authors:  Jyotirmoy Banerjee; Aparna Banerjee Dixit; Manjari Tripathi; Chitra Sarkar; Yogendra Kumar Gupta; P Sarat Chandra
Journal:  Epilepsy Res       Date:  2015-08-12       Impact factor: 3.045

9.  Expression and cell distribution of group I and group II metabotropic glutamate receptor subtypes in taylor-type focal cortical dysplasia.

Authors:  Eleonora Aronica; Jan A Gorter; Gerard H Jansen; Cees W M van Veelen; Peter C van Rijen; Marja Ramkema; Dirk Troost
Journal:  Epilepsia       Date:  2003-06       Impact factor: 5.864

10.  Altered glutamatergic tone reveals two distinct resting state networks at the cellular level in hippocampal sclerosis.

Authors:  Jyotirmoy Banerjee; Aparna BanerjeeDixit; Arpna Srivastava; Bhargavi Ramanujam; Aanchal Kakkar; Chitra Sarkar; Manjari Tripathi; P Sarat Chandra
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.